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Abstract We investigated the in vitro cytotoxic effects of CPT -11， a new derivative 
of camptothecin， and its metabolizable form in vivo， SN -38， on cisplatin-resistant (SHIN 
3) and-sensitive (MN -1) ovarian cancer cel lines using the MTT assay. We also 
aUempted to identify the .optimal schedule of administration for cisplatin combined with 
low-dose continuous exposure to CPT -11 (3μg/ml) or SN-38 (5 ng/ml). With either CPT 
11 or SN -38 alone， a marked schedule-dependent inhibition of growth was obtained with 
exposure for over 40 hours to concentrations of those agents applicable to clinical use (CPT 
11: く7.58μg/ml，SN-38 :く72ng/ml)， even in a cisplatin-resistant cellline. Increasing 
the assay AUC of these agents only by dose escalation did not enhance cytotoxity with both 
MN-1 (CPT-11 : 3-50μg/ml， SN-38 : 2.16-72 ng/ml) and SHIN-3 (CPT-11 : 5-50μg/ml， 
SN -38 : 21.6-720 ng/ml) cel lines up to 72 hours of exposure. Pretreatment of SHIN-3 
cells with either CPT-11 (3μg/ml) or SN -38 (5 ng/ml) for 48 hours before the administra】
tion of cisplatin (4-20μg/ml) appeared to produce an inhibition which exceeded that 
produced by either a longer (96 hours) or shorter (0 hour) pretreatment with them. Flow 
cytometric analysis showed that treatment with CPT-11 and SN -38 in SHIN -3 cellline was 
associated with a peak in G2/M phase at 24 hours and an increase in the GO/G1 phase 
fraction for up to 96 hours. It is thus suggested that the continuous administration of a low 
dose of CPT-11 or of SN -38 may be useful clinically. The in vitro cytotoxicity of cisplatin 
could be increased by pretreatment with either CPT -11 or SN -38. 
Index Terms 
CPT-11， SN-38， cisplatin， combination chemotherapy， overian cancer 
The abbreviations used here are : MTT， 3-(4，5-dimethyl thiazol-2-yl)-2，5-diphenyl tetr-
azolium bromide ; AUC， area under the curve ; CPT-11， 7-ethyl-10 [4-(1-piperidino)-1-
piperidino] carbonyloxy-camptothecin ; SN -38， 7-ethyl-10-hydroxy-CPT ; DMSO， dimeth-
Address for reprint requests : Tsuneo NODA， Department of Obstetrics and Gynecology， Higashi Osaka Central 
Municipal Hospital， 2-3-1 Mikuri-Minami， Higashi Osaka-shi， Osaka 57， ]apan 
(274) T， Noda， etal 
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INTRODUCTION 
While podophyllotoxin was identified as a cytostatic agent in the 1940s， the available 
derivatives were highly toxic， Etoposide， a more recent glycosidic derivative of podophyllotox】
in， exhibits marked clinical activity against a wide variety of neoplasms， including lung cancer， 
lymphoma， and gynecologic malignancies1.2)， This agent may exert its cytotoxic effects， inpart， 
by interfering with the scission-reunion reaction of topoisomerase IJ3l， Breakage of DNA 
strapds are detected at concentrations of etoposide significantly below those required to affect 
cell kinetics and DNA synthesis4)， Etoposide-related inhibition of topoisomerase I is revers-
ible， and DNA strand breaks are repaired rapidly after the drug is discontinued5)， 
Etoposide is one of the few antineoplastic agents that is effective as a second-line 
treatment6) ; it may be synergistic with cisplatin7)， The schedule dependency of etoposide was 
first demonstrated in early preclinical investigation8)， Clinically， patients with small-celllung 
cancers given etoposide as five consecutive daily infusions showed a response rate of 89%， being 
superior to results obtained by giving a continuous intravenous infusion for 24 h， This suggests 
the importance of a longer duration of etposide administration at concentrations above 1μg/ 
ml in obtaining eficacy9)， 
Camptothecin (CPT)， a plant alkaloid derived from Camρtotheca acum仇atum，was isolated 
by Wall et al. in 196610)， While this agent demonstrated a good spectrum of activity against 
numerous cancer models， its clinical use was limited by severe toxicity， Miyasaka et al. then 
developed CPT-11 (7-ethyl-10一[4-(l-piperidino)-1-piperidino]carbonyloxycamptothecin) as 
an alternative to CPTll)， CPT-11 is less toxic and shows increased tumor activity as compared 
to CPT. It is also water-soluble， CPT -11 exhibits significant antitumor activity against 
various experimental tumor models12)， In a clinical stuby of 39 various tomors obtained from 
patients， CPT-11 produced an overall response rate of 44%， A particularly good response 
(56%) was observed in ovarian cancer13)， In a phase I study conducted in J apan， monotherapy 
with CPT-11 induced a clinical response in 35% of the patients with advanced ovarian cancer 
treated with this agent14) 
The cytotoxic mechanism of CPT-11 has not been established， although inhibition of the 
nuclear enzyme topoisomerase 
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MATERIALS AND METHODS 
Ovarian cancer cel lines 
We investigated the effects of CPT-11 on SI-IN-3 cells， ovarian serous cystadenocarcinoma 
cells which we had obtained from a patient who developed resistance to cisplatin16). In addition， 
we studied results in the MN  -1cellline developed from a patient with mucinous cystadenocar目
cinoma responsive to cisplatin-based chemotherapy17). 
Both cel lines were incubated in Dalbecco's minimum essential medium (DMEM) sup-
plemented with 10% FCS (GIBCO， Grand Inland， NY)， 100 units/ml penici1lin， and 0.3 mg/ml 
glutamine at 37'C in a humidified atmosphere of 5% CO2 in air. 
For the cytotoxicity assay， 5 X 103 to 1 X 104 cells per 50μ1 of culture medium were plated onto 
96-well multiplates and incubated for 24 hours before the addition of drugs. 
Drugs 
CPT -11 (provided by Daiichi Pharmaceutical Co.， Ltd.， Tokyo， J apan) was reconstituted in 
disti1led water at a concentration of 20 mg/ml and SN -38 (Daiichi) was reconstituted in a 
sterile dimethyl sulfoxide (DMSO) at a concentration of 10 mg/m1. These substances were 
diluted with FCScontaining DMEM to final concentration immediately before use. Cisplatin 
(provided by Nippon Kayaku Co.， Ltd.， Tokyo， J apan) was diluted in disti1led water to a 
concentration of 0.5 mg/m1. Diluted CPT-11 and cisplatin were each stored at 4"C， while SN 
-38 was stored at -20"C. The final concentration of DMSO in culture medium was adjusted 
to less than 1.0 % (V /V)， which was confirmed in preliminary studies to have no antiprolifer-
ative effect on either cel line (data not shown). 
MTT a呂田ay
The MTT assay was performed as previously described18). In brief， the number of cells 
plated onto 96 wells was determined after preliminary studies of cel growth using the MTT 
assay (data not shown) so that the untreated cells were in the exponential growth phase during 
the experiment. CPT -11 or SN -38 050μ1 of 4/3 fold concentration of drug di1uted in medium) 
was added to the incubated cells (5 x 103 to 1 X 104cells/wel1 in 50μ1 of medium) in the 
multiplates. FCS concentration in each sample was adjusted at 10% (V /V). We studied the 
effects of 10 different concentrations of CPT-11 and of SN -38， covering a 4-10g range， that 
spanned the 50% inhibitory concentration， as determined by preliminary assays (data not 
shown). After cel1s were cultured， l3μ1 (5 mg/ml) of MTT (Sigma Chemical Co.， St. Louis， 
MO) diluted with phosphate-buffered saline (PBS， pH 7.6) was added to each 
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was determdned by the MTT assay. Additional control experiments used culture medium 
alone. Fractional absorbance after treatment was expressed as the percentage of control 
absorbance : that is， the absorbance levels from drug-treated cells were corrected by the 
untreated contral absorbance values， from which we defined the schedule-and concentration 
dependent growth inhibition curves. The inhibitory concentration(IC)so was defined as a 50% 
reduction of absorbance as determined by the MTT assay 
The AUC (area under the curve) value of the assay expressed as μg/mlehour was deter-
mined using the drug stability data described by Hildebrand-Zanki et al. 19). The assay AUC 
was calculated by multiplying the concentration of drug by the duration of assay. We 
determined the relation between the growth inhibition induced by CPT -11 or SN -38， and the 
assay AUC. 
Combination of CPT-ll or of SN -38 with cisplatin 
The IC10 values of CPT-11 or SN-38 after 72-hour incubation with the SHIN-3 cellline， 
determined from the growth inhibition curves， were selected as those to be used in combination 
with cisplatin treatment. IC10 values were 3μg/ml for CPT-11 and 5ng/ml for SN-38 
CPT -11 or SN -38 were continuously administrated for 6 consecutive days. Cisplatin was 
added on day 1 (group 1)， day 3 (group I)， or day 5 (group II) for 24 hours. Doses of 4， 10， 
and 20μg/ml cisplatin were administrated to each group (Fig.l). Additional cel samples were 
treated with cisplatin alone on days 1， 3， or 5 (group 1'， I'， or II')， or with CPT-11 or SN-38 
alone. Untreated samples were used as controls. The number of cells after treatment was 
determined by the MTT assay and expressed as the relative absorbance (% of control 
absorbance). The effectiveness of the administration schedule for cisplatin (relative rate of 
inhibition) was determined by the following formula : 
Relative rate of inhibition (%) [(A -B) -;A] X 100 
where A is % of control absorbance in the group treated with cisplatin alone， and B is % of 
control absorbance in the group treated with combination therapy 
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Fig. 1. Drug administration schedule for巴valuatingrelative rate of growth 
inhibition. CPT-ll (3μg/mO or SN-38 (5 ng/mO plus cisplatin (4， 
10 and 20，ug/mO， or cisplatin alone， was added to SHIN-3 cel line 
Duration of preincubation before administering each agent was 12 
hours. 
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cell number， the change in pH， and the effect of Go phase arrest that may occur when the 
medium is changed. 
Flow cytometry 
SHIN -3 cells at a concentration of 5 x 105 were plated in 75一cm2culture flasks and incubated 
for 24 hours. N ext， 3μg/ml of CPT-11 or of 5ng/ml of SN-38 was added tothe cels. After 
cu1ture for 24 to 96 hours， the control， CPT -l1-treated， or SN -38-treated cells were harvested 
by trypsinization. Cells were filtered through a 60μm metal mesh， treated with 0.01 % RN ase 
(Type 1A， Sigma Chemical Co.， St.Louis， Mo) and then stained with propidium iodine (50μg/ 
ml). The amount of nuclear DNA in the stained samples was measured by FACStar flow 
cytometer (Nippon Becton Dickinson Co.， Tokyo， Japan) with CELLFIT program. 
The change in cell cyclic phase fraction during drug exposure was determined. 
Statistical methods 
Data points represent the mean and one SD of 8 wells in monotherapy with CPT -11 or SN 
-38， and of 16 wells in combination treatment. Statistical significance was determined by using 
the paired Student's t-test to compare the relative rates of inhibition in each group. A P value 
less than 0.05 was considered statistically significant. 
RESULTS 
Cell culture 
Cells were routinely subcultured by trypsin/EDT A treatment with a split of 1 : 4.Under the 
conditions of our experiment， the logarithmic growth phase took about 140 hours in 96-well 
plates following inoculation of 5 x 103 cells/well. The doubling time of the SHIN -3 cells (27 
hours) and of MN  -1 cells (23 hours) did not differ in each passage. 
Cytotoxic effect of CPT-l1 or of SN -38 on SHIN -3 and MN  -1cel lines 
Exposure of SHIN -3 cells to CPT-11 resulted in IC50 values of 280μg/ml at 24 hours， 150μg/ 
ml at 48 hours， 130μg/ml at 72 hours， and 18μg/ml at 94 hours (Fig. 2). N 0 IC50 was achieved， 
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Fig. 2. Effect of CPT-ll on SHIN-3 celline. Cel were incubated for 24 to 94 
hours. PPC : peak plasma concantration目
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of 7.58μg/ml. The PPC of CPT-11 was determdned as a result of administering the maximal 
tolerated dose in a phase I clinical triaF4). The response curve indicated a concentration-and 
schedule-dependent effect over PPc. Exposure of SHIN -3 cells to SN -38 resulted in IC50 
values of 3000 ng/ml at 24 hours， 1500 ng/ml at 46 hours， 500 ng/ml at 72 hours， and 150 ng/ml 
at 94 hours， al of which exceeded the PPC of SN -38. The response appeared to be concentra-
tion-dependent over 720 ng/ml. However， a schedule-dependent effect was observed at and 
below the PPC CFig. 3). 
IC50 values werenot observed during 20-hour exposure of MN  -1cells to CPT-11 or SN -38. 
A concentration-dependent effect was observed after 40 hours of exposure， resulting in an IC50 
value of 2.6μg/ml at 40 hours for CPT -11， and 2.5 ng/ml for SN -38. These IC50 values were 
below the clinically determined PPc. After exposure for 64 hours， IC50 values were 0.4μg/ml 
for CPT-11 and below 0.72 ng/ml for SN -38 CFigs. 4，5). Response curves revealed that the MN  
-1 ce1l1ine exhibited a greater sensitivity to CPT-11 and to SN-38 than did the SHIN-3 cel 
liロe.
Correlation between growth inhibition and AUC induced by CPT-ll and SN-38 
There were no significant differences in the effects of CPT-11 at doses of l.0 to 100μg/ml 
on MN--1 cells with treatment given for 20 hours. The degree of inhibition decreased at 
concentrations under 0 . 5μg/ml. AUC-dependent cytotoxicity was observed after exposure for 
40 hours， but was not apparent after exposure for 64 hours at concentrations above 1.0μg/ml 
CFig. 6). The same tendency was observed with SN-38. A significant AUC-dependent 
inhibition of growth was also observed with treatment given over 20 hours ; however， itwas 
saturated above a concentration of 2.16 ng/ml over 64 hours CFig. 7) 
CPT-11 was associated with an AUC-dependent inhibition of growth of SHIN-3 cels. The 
steepest response curves were seen at concentrations of 5 to 50μg/ml. N 0 significant AUC-
dependent inhibition of growth was observed at concentration below 3μg/ml CFig. 8). AUC-
dependent growth inhibition was observed with concentrations of SN -38 below 720 ng/ml. 
Concentrations of 7.2 to 72 ng/ml were associated with a growth inhibition below 5G%， while 





















































































Concentration of SNω38 
Fig. 3. Effect of SN -38 on SHIN -3 cel1lin巴.Cel1 were incubated for 24 to 94 
hours. PPC : peak plasma concentration目
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Fig. 4目 Concentrationand sch巴dul巴 d巴pendentresponse curv巴 ofCPT-11 to 






















10 100 1000 10000 (~g/ml ， hrs.) 
AUC induced by administering CPT目 1
Fig. 6. Relation between growth inhibition and AUC induced by CPT-11 in 
MN -1cels. CPT -11 conc巴ntrationswer巴 rang巴dfrom 0.3 to 300μg/ 
ml and cells were incubated for 20 to 64 hours 
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10 100 1000 10000 (ng/ml， hrs.) 
AUC induced by administering SN-38 
Fig. 7. Relation between growth inhibition and AUC induced by SN -38 in MN  
-1 cel1s. SN-38 concentrations w巴reranged from 0.72 to 720 ng/ml and 







10 100 1000 10000 (μg/ml， hrs.) 
AUC induced by administering CPT-ll 
Fig. 8. Relation between growth inhibition and AUC induced by CPT-ll in 
SHIN-3 cel1s. CPT-ll concentrations w巴r巴rangedfrom 0.3 to 300μg/ 
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AUC induced by administering SN-38 (ng/ml，h悶)
Fig. 9. Relation between growth inhibition and AUC induced by SN-38 in 
SHIN-3 c巴l1line.SN -38 concentrations were ranged from 7.2 to 36000 
ng/ml and cel1s were incubated for 24 to 94 hours 
Cytotoxicity of combined CPT-ll (SN-38) and cisplatin (281) 
Only a schedule depencency was prominent over 46 hours. N 0 significant dependency on the 
AUC was observed with doses over 7200 ng/ml CFig. 9). 
Combination CPT-ll or SN -38 with cisplatin 
The relative rate of inhibition tended to increase in association with an increase of CPT-11 
preincubation time in the groups exposed to combination therapy compared with those given 
cisplatin alone. 1n combination with 4 to 20μg/ml of cisplatin， the inhibitory rates were 
maximum as 42.9:t4.2 (P<0.005 to groups 1-1' and II-II') and 77.8士15.6% (P<0.005 to 
groups II-II'， P<0.10 to groups 1-1') between group III and III¥The maximum rate of 60.5土
13.6 % at a concentration of 10μg/ml of cisplatin was observed in groups I and II'(P<0.05 
Table 1. Relative rates of inhibition ( 1 'ー I/I'， U'-II/I'， III'~III/IIIつ
det巴rminedby %control of absorbance in groups tr巴atedwith 
cisplatin alone ( 1'， U'， IIつandwith combination therapy of 
CPT-ll and CDDP (1， I， II) (m巴an土SD)
CDDP 
4μg/ml 10μg/ml 
% control of absorbance 
1 ' 46.5土8.6 19.2土4.0
40.4士3.8 10.7士l.8




Relative rate of lnh出 tion
I'-I/I' 15.0士10.6" 55.9士9.4d
I' -II/ I' 28.8土5.5b 60.5士13.6'
II' -1I/1I' 42.9士4.2' 29.5士3.6'
p<O目005: a to b and c， b to c， d to f， e to f， h to i， 
Pく0.05: d to巴 p<0.10:g to i 











Table 2. Relative rates of inhibition (1 '-1 / 1'， U'-II/U'， II'-II/IIつ
determined by % control of absorbance in groups tr巴atedwith 
cisplatin alone ( 1'， U'， IIつandwith combination therapy of 
SN-38 and CDDP (1， I， II)(mean土SD)
CDDP 
4μg/ml 10μg/ml 20μg/ml 
%control of absorbanc巴
1 ' 16.5土8.3 4l.0土3.1 7.8土l.0
57.8士8.0 55.6士23.3 6.8士3.3
I' 85.1土10.。 79.2土7.3 64目7土4.1
I 67.3士7.9 53.9士6.3 34.3士13.3
lI' 89.1土10.7 84.9土6.6 82.2土10.7
1I 8l. 6士5.2 68. 9:!:5. 4 56. 7:!:7.2 
Relative rate of inhibition 
I'-I/I' 6目9土4.2a 2.4士l.7d 12.4土2.1g 
I' -I / I' 20.9士4.1b 32.0士3.1' 57.4士2.6h
II' -1I / lI' 10目1土5.5' 18.8土3.5' 28.6土3.4'
pくO.005 : a to b， b to c， d， toe and f， g to h and i， h to i 
N. S. : a to c CStudent's t-test) 
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Table 3. Changes in c巴1cyclic piase fractions after CPT-l1 
(3μg/m!)or SN -38 (5 ng/m!) treatment in SHIN -3 cel line 
CPT-ll SN-38 
















12.1 57.7 30.2 12.1 57.7 
14.7 27目。 58.3 20.0 25.2 
2.9 32.1 45.0 25.5 38.2 
20.1 32.4 47目4 34.6 39.5 






to groups II -II'， P < 0 . 5 to groups 1-1つ(Table1). 
In combination therapy with SN -38， the maximum relative rate of inhibition was indicated 
between groups I and I' with the preincubation time for 48 hours. They were 20.9:!: 4.1 % in 
the combination with 4μg/ml of cisplatin， 32.0:!:3.1 % at 10μg/ml， 57.4士2.6% at 20μg/ml 
(P < 0.005 to groupsI -l' and groups I -I') (Table 2). 
Flow cytometric analysis 
The greatest extent of G2/M phase arrest was achieved just after exposing the SHIN -3 cells 
to 3μg/ml CPT-11 for 24 hours. The percentage of cells in the S phase decreased from 57.7 
to 27.0 % after 24-hour exposure ; the GO/G1 phase fraction increased gradually from 12.1 to 
27.0 % (Table 3). 
The same tendency was observed with the 5 ng/ml dose of SN -38. However， the number of 
cells in the S pahse exceeded that in the G2/M phase after 48 hours (Table 3). 
DISCUSSION 
Although significant advances have been made in treating advanced ovarian cancer， espe目
cially with the introduction of cisplatin about 15 years ago， less than 20% of the patients 
experience a long-term disease-free survival after cisplatin-based treatment. 
CPT-11， developed in Japan， isa new derivative of the plant alkaloid CPTll1. CPT and most 
of its derivatives， such as 7-ethyl-CPT (SN-22)， lO-hydroxy-CPT， and 7-ethyl-10-hydroxy-
CPT (SN-38)， are insoluble in water in the forms used c1inically. CPT-11 exhibited greater 
anti-tumor activity and less toxicity than CPT121. In an experimental study， CPT -11 demon-
strated the apparent cure of a variety of susceptible murine tumors inc1uding S-180， Meth-A 
fibrosarcoma， Lewis lung carcinoma， Ehrlich carcinoma， MH -l34 hepatoma， mammary car同
cinoma of C3H/HeN mice， Ll210 leukemia， and P388 leukemia， suggesting that it has a broad 
spectrum of activity121. 
By subrenal capsule assay， CPT -11 demonstrated an overall chemo sensitivity rate of 44% 
in 39 samples of various tumors， with a statistically significant response of 56% observed in 10/ 
18 ovarian cancer samples13. 
A phase 1 c1inical stuby demonstrated that the maximum tolerated dose of CPT -11 was 250 
mg/m2 (q 3-4w)201. An early phase I study suggested that the optimal dose schedule was.200 
mg/ml every 3 to 4weeks14. CPT -11 is believed to be changed into SN -38， via hepatic 
metabolism 12 
Most antineoplastic agents used to treat gynecologic malignancies act as DNA intercalators. 
Cytotoxicity of combined CPT-ll (SN -38) and cisplatin (283) 
Agents such as etoposide， a topoisomerase I inhibitor， and taxol have different mechanisms of 
action and have been scown effective in patients with platinum-resistant ovarian cancer21). A 
combined regimen of low-dose continuous etoposide and cisplatin has been proposed as second 
-line therapy for such cases22). 
1n a previous study， we determined the optimal schedule for administering cisplatin in 
combisation with low-dose etoposide by determining its cytotoxic effect in vitro23). 1n the 
present study， we used the same method to investigate the effects of CPT-11. 
We investigated the effects of CPT -11 in two lines of human ovarian cancer cells， SH1N -3， 
which is cisplatin-resistant， and MN -1， which is cisplatin-sensitive. 1n previous experiments， 
the SH1N -3 cell line demonstrated a weak response to 8.0μg/ml of cisplatin after 72-hour 
exposure as the 1C5o value to untreated control ; the MN  -1cel line demonstrated a response 
to 1.8μg/ml of cisplatin after 48-hour exposure23). 
A single dose of CPT -11 or of SN -38 exerted a strong cytotoxic effect over PPC on MN-1 
cels. When cells were exposed to CPT -11 or SN -38 for over 40 hours， 1C5o values were easily 
achieved even when drug concentrations were below the clinically determined PPC. AUC-
dependent growth inhibition was also observed at the same condition of exposure. 1n treating 
ovarian cancer， it may be advantageous to administer CPT -11 by a continuous infusion over 40 
hours to treat cisplatin-sensitive overian cancers in the clinical setting. The SH1N -3 cel line 
showed cross-resistance to CPT -11 and SN -38， as indicated by the absence of an 1C5o， even 
after 96 hours of exposure at concentrations below the PPC. It is possible that only a schedule 
dependent program of administration would exhibit anti-tumor efficacy in treating cisplatin 
-resistant ovarian cancer. When AUC was accelerated by increasing the dose of CPT -11 or SN 
-38 to the clinically applicable concentration， growth inhibition did not rise significantly over 
prologed exposure. 
1n our previous study， the number of viable cancer cells treated with cisplatin gradually 
decreased even after the washout of cisplatin， indicating that the cytocidal effect of cisplatin 
gradually appeared in vitro for over 24 hours23)目 Therefore，it was not possible to compare 
cytotoxic effects among groups 1， I， and 1I in the present study because of differences in the 
duration until MTT assay. We therefore e 
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the Go/G， phase fraction increased gradual1y up to 96 hours. These changes may be involved 
in the cytocidal mechanism of CPT -11. Exposure of SHIN -3 cel1s to 1μg/ml etoposide 
significantly increased the Go/G， phase fraction at 100 hours， and the peaks of G2/M and S 
phase at 20 hours23). We found similar results with CPT -11 or SN -38， except for the motion 
of the S phase fraction 
Although the in vitro pharmacological effects of CPT -11 should be studied using SN -38， its 
metabo1izable form， our results may be useful in determining the schedule for administering 
CPT -11 in the clinical setting. Our findings showed that low-dose continuous treatment of 
ovarian cancer cel1s with CPT-11 or SN-38 for over 40 hours had beneficial effects. Pretrea:t-
ment with these agents in rather low concentration for over 48 hours before the administration 
of cisplatin appeared to be the most effective combination regimen. 
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